Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Good Start Genetics, PerkinElmer Collaboration Expands Access to Genetic Carrier Screening Tests

Published: Monday, March 17, 2014
Last Updated: Monday, March 17, 2014
Bookmark and Share
Strategic agreement will broaden access to GoodStart Select™ tests to include obstetrics and gynecology and maternal fetal medicine physicians.

GoodStart Select is a menu of genetic carrier screening tests offered by Good Start Genetics that uses sophisticated technologies, including proprietary next-generation DNA sequencing (NGS), to provide highly accurate and clinically actionable genetic information to reproductive partners planning a pregnancy. Test results by GoodStart Select have been shown to provide higher mutation detection rates and fewer missed carriers than traditional screening technologies.

"Our continued success with GoodStart Select in the IVF setting demonstrates the clinical value of our robust menu of tests for guideline-recommended genetic disorders. We are excited that PerkinElmer has chosen GoodStart Select as their genetic carrier screening offering of choice," said Don Hardison, president and chief executive officer of Good Start Genetics. “Collaborating with PerkinElmer will allow us to reach more of the 60 million reproductive age women who are candidates for genetic carrier screening, and ultimately help more couples better assess their risks of, and options to avoid, having a baby with a debilitating or fatal inherited genetic disorder ."

Under the terms of the collaboration agreement, PerkinElmer will serve as the exclusive commercial partner of Good Start Genetics in the sales and marketing of GoodStart Select to targeted OBGYN and MFM physicians in the United States. The collaboration expands access to the GoodStart Select tests to ordering physicians that are not within Good Start Genetics’ current commercial market of in vitro fertilization and broadens PerkinElmer’s extensive prenatal screening menu to include the highly-validated genetic carrier screening tests included in the GoodStart Select menu.

"PerkinElmer is committed to offering innovative prenatal screening technology as part of our comprehensive diagnostics portfolio,” said Jim Corbett, president, Human Health, PerkinElmer. “GoodStart Select further expands our maternal fetal health offerings and enables us to provide even more meaningful tools and clinically actionable information and insights to physicians and patients. We look forward to working with Good Start Genetics to extend genetic carrier screening options for those persons planning a pregnancy.

Professional societies, including the American Congress of Obstetricians & Gynecologists (ACOG), the American College of Medical Genetics and Genomics (ACMG) and national Jewish advocacy societies have published recommendations for carrier screening to detect potential genetic disorders that are relatively common in certain ethnicities. GoodStart Select is designed to identify known, pathogenic mutations for all inherited genetic disorders recommended for testing by the leading reproductive medicine societies and influential advocacy groups, irrespective of a patient’s ethnicity. By arming physicians and patients with this personalized genetic information, GoodStart Select can help reproductive partners to better assess their risk of, and options to avoid, having a child with a debilitating or fatal inherited genetic disorder.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PerkinElmer, Sofie Biosciences Announce Benchtop PET Imaging Partnership
Preclinical PET imaging instruments in benchtop format help support high performance disease research, drug discovery and clinical translational applications.
Tuesday, June 10, 2014
PerkinElmer to Host Revolutionaries for Global Health Summit
Company to assemble thought leaders to share pioneering personalized health research and innovations.
Wednesday, May 01, 2013
PerkinElmer Expands Reagent Portfolio for Faster Identification of Epigenetic Drug Candidates
The company announced the launch of four new cellular assay kits to help identify and characterize possible drug candidates targeting epigenetic enzymes related to key disease states.
Tuesday, February 07, 2012
Scientific News
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos